Use of Docosahexaenoic Glycerides For The Treatment Of Tumorous Diseases

Abstract

The present invention relates to the use of an oil enriched in docosahexaenoic acid, which is conjugated to triglyceride, for manufacturing a pharmaceutical composition for the treatment of a tumorous disease, said oil being enriched in a concentration of up to 70% by weight in relation to the total weight of said pharmaceutical composition, and said docosahexaenoic acid being in a percentage of at least 50% in relation to the total fatty acids in said oil.

1 . A method for treating a tumor which comprises administering to a patient a pharmaceutical composition comprising an oil enriched in DHA triglyceride, and wherein said DHA triglyceride being in a percentage of at least 50% in relation to the total fatty acids in said oil. 
     
     
         2 . The method according to  claim 1 , characterized in that said pharmaceutical composition is in emulsion form. 
     
     
         3 . The method according to  claim 1 , wherein said enriched oil comprises eicosapentaenoic acid in a percentage by weight of up to 30% in relation to the total fatty acids of said oil. 
     
     
         4 . The method according to  claim 1 , wherein the concentration of DHA triglyceride is in a percentage of 70%-90% by weight in relation to the total fatty acids of said oil. 
     
     
         5 . The method according to  claim 1 , wherein said DHA triglyceride is in a percentage of 70% by weight in relation to the total fatty acids in said oil. 
     
     
         6 . The method according to  claim 2 , wherein the mean diameter of the emulsion is less than 200 nm. 
     
     
         7 . The method according to  claim 1 , wherein said pharmaceutical composition is administered by parenteral route. 
     
     
         8 . The method according to  claim 1 , wherein said pharmaceutical composition is administered by intratumor injection. 
     
     
         9 . The method according to  claim 1 , wherein said pharmaceutical composition is administered to a patient who is receiving concomitantly at least one antineoplastic drug. 
     
     
         10 . The method according to  claim 1 , wherein the tumor to be treated is one of the group that includes: lung, prostate, bowel, breast, pancreas, brain, central and peripheral nervous system, and melanoma. 
     
     
         11 . The method according to  claim 1  wherein the tumor to be treated is of a haematological nature. 
     
     
         12 . A method for treating a tumor which comprises administering to a patient a pharmaceutical composition comprising an oil enriched in DHA triglyceride, wherein said oil comprises at least 50% by weight of a DHA triglyceride, and wherein said DHA triglyceride being in a percentage of at least 50% in relation to the total fatty acids in said oil. 
     
     
         13 . The method according to  claim 12 , characterized in that said pharmaceutical composition is in emulsion form. 
     
     
         14 . The method according to  claim 13 , wherein said enriched oil comprises eicosapentaenoic acid. 
     
     
         15 . The method according to  claim 12 , wherein the enriched oil comprises at least 10% of the total weight of the pharmaceutical composition. 
     
     
         16 . The method according to  claim 12 , wherein the enriched oil comprises between 50% to 100% of the total weight of the pharmaceutical composition. 
     
     
         17 . The method according to  claim 12 , wherein the enriched oil comprises between 70% to 90% of the total weight of the pharmaceutical composition. 
     
     
         18 . The method according to  claim 12 , wherein the DHA triglyceride is in a percentage of 70% to 90% in relation to the total fatty acids of said oil. 
     
     
         19 . The method according to  claim 12 , wherein the pharmaceutical composition is administered by parenteral route. 
     
     
         20 . The method according to  claim 12 , wherein the pharmaceutical composition is administered by intratumor injection. 
     
     
         21 . The method of  claim 12 , wherein the tumor to be treated is selected from the group consisting of: lung, prostate, bowel, breast, pancreas, brain, central and peripheral nervous system, and melanoma.